Skip to main content

Advertisement

SpringerLink
Log in

Immunophenotype and Human Papillomavirus Status of Serous Adenocarcinoma of the Uterine Cervix

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Serous adenocarcinoma of the cervix (SACC) is a very rare tumor. Our study aimed to characterize the immune profile and human papillomavirus (HPV) status of SACC, in comparison with other serous adenocarcinomas arising in the female genital tract. The pathological specimens obtained from 81 patients with serous carcinoma of the uterine cervix (n = 12), 29 endometrium, 20 ovary and 20 patients with mucinous carcinoma of the uterine cervix were reviewed. We assessed the expression of WT-1, p53, p16, HER2, CEA, and CA125 by immunohistochemistry and HPV DNA by PCR in 12 SACC samples. Their immune profile was compared with that of uterine papillary serous carcinoma (UPSC), ovarian serous adenocarcinoma (OSA), and mucinous endocervical adenocarcinoma (MEA). WT-1 and HER2 were expressed in very few SACC samples (0 and 0 %, respectively), but p16, CA125, CEA and p53 were present in 100, 92, 58 and 50 %, respectively. The difference in WT-1 expression between SACC and UPSC, MEA is not significant, but SACC differ significantly from OSA (p < 0.01). HPV DNA (type 16 or 18) was detected in 4 of the 12 SACC. The immunophenotype of SACC was similar to UPSC, whereas the frequency of expression of WT-1 was significantly lower in SACC than OSA. It appeared that p53 expression was associated with worse clinical outcome in patients with SACC, and that HPV infection was related to its occurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG (2008) Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol 110(3):293–298

    Article  CAS  PubMed  Google Scholar 

  2. Zhou C, Gilks CB, Hayes M, Clement PB (1998) Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. Am J Surg Pathol 22(1):113–120

    Article  CAS  PubMed  Google Scholar 

  3. Togami S, Kasamatsu T, Sasajima Y, Onda T, Ishikawa M, Ikeda SI, Kato T (2012) Tsuda H serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature. Gynecol Obstet Investig 73(1):26–31

    Article  Google Scholar 

  4. Bocker W (2002) WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol 86:116–119

    CAS  PubMed  Google Scholar 

  5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43

    CAS  PubMed  Google Scholar 

  6. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ (1995) The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76(Pt 4):1057–1062

    Article  PubMed  Google Scholar 

  7. Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhorst TJ (2007) Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer 121(1):106–110

    Article  CAS  PubMed  Google Scholar 

  8. Hunt CR, Hale RJ, Buckley CH, Hunt J (1996) p53 expression in carcinoma of the cervix. J Clin Pathol 49(12):971–974

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Tsuda H, Jiko K, Tsugane S, Yajima M, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, Sonoda T, Hirohashi S (1995) Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res 86(11):1049–1053

    Article  CAS  PubMed  Google Scholar 

  10. Batistatou A, Zolota V, Tzoracoleftherakis E, Scopa CD (2000) Papillary serous adenocarcinoma of the endocervix: a rare neoplasm. Immunohistochemical profile. Int J Gynecol Cancer 10(4):336–339

    Article  PubMed  Google Scholar 

  11. Nofech-Mozes S, Rasty G, Ismiil N, Covens A, Khalifa MA (2006) Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer 16(Suppl 1):286–292

    Article  PubMed  Google Scholar 

  12. Broker TR, Jin G, Croom-Rivers A, Bragg SM, Richardson M, Chow LT, Vermund SH, Alvarez RD, Pappas PG, Squires KE, Hoesley CJ (2001) Viral latency–the papillomavirus model. Dev Biol 106:443–51, discussion 452–3, 465–475

    CAS  Google Scholar 

  13. Fontaine J, Hankins C, Mayrand MH, Lefevre J, Money D, Gagnon S, Rachlis A, Pourreaux K, Ferenczy A, Coutlee F (2005) High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV. AIDS (London, England) 19(8):785–794

    Article  Google Scholar 

  14. Riethdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP (2002) Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 33(9):899–904

    Article  CAS  PubMed  Google Scholar 

  15. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP (1999) Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 37(4):1030–1034

    PubMed Central  CAS  PubMed  Google Scholar 

  16. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E (2001) The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37(2):246–250

    Article  CAS  PubMed  Google Scholar 

  17. Missaoui N, Hmissa S, Frappart L, Trabelsi A, Ben Abdelkader A, Traore C, Mokni M, Yaacoubi MT, Korbi S (2006) p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 448(5):597–603

    Article  PubMed  Google Scholar 

  18. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM, Isacson C (2000) Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 157(4):1055–1062

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG (2007) Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 26(3):328–333

    Article  PubMed  Google Scholar 

  20. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1):63–73

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Franco EL, Rohan TE, Villa LL (1999) Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91(6):506–511

    Article  CAS  PubMed  Google Scholar 

  22. Nofech-Mozes S, Khalifa MM, Ismiil N, Dube V, Saad RS, Sun P, Seth A (2010) Ghorab Z Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol 18(1):80–85

    Article  CAS  PubMed  Google Scholar 

  23. Hadzisejdc I, Krasevic M, Haller H, Grahovac B (2007) Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Anthropol 31(Suppl 2):97–102

    Google Scholar 

  24. Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23(2):110–118

    Article  PubMed  Google Scholar 

  25. Hashi A, Yuminamochi T, Murata S, Iwamoto H, Honda T, Hoshi K (2003) Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 22(4):374–377

    Article  PubMed  Google Scholar 

  26. Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, Odunsi K (2006) Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol 101(1):12–17

    Article  CAS  PubMed  Google Scholar 

  27. Lin X, Lindner JL, Silverman JF, Liu Y (2008) Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities. Appl Immunohistochem Mol Morphol 16(5):453–458

    Article  PubMed  Google Scholar 

  28. Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, Ghorab Z (2008) Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 21(9):1147–1155

    Article  CAS  PubMed  Google Scholar 

  29. Deavers MT, Malpica A, Silva EG (2003) Immunohistochemistry in gynecological pathology. Int J Gynecol Cancer 13(5):567–579

    Article  CAS  PubMed  Google Scholar 

  30. Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB (2003) Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442(3):271–277

    CAS  PubMed  Google Scholar 

  31. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104(7):1391–1397

    Article  CAS  PubMed  Google Scholar 

  32. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH (2004) Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22(15):3126–3132

    Article  CAS  PubMed  Google Scholar 

  33. Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T (2012) Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 103(5):926–932

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Sachiko Miura, M.T., and Chizu Kina, M.T. for technical support.

This work was supported in part by a grant-in-aid for Development of Cancer Research.

Conflict of Interests

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gynecology, National Cancer Center Hospital, 5-1–1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Shinichi Togami, Takahiro Kasamatsu, Satoshi Okada, Mitsuya Ishikawa, Shun-ichi Ikeda & Tomoyasu Kato

  2. Department of Obstetrics and Gynecology Department of Molecular and Cellular Pathology, Field of Oncology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan

    Shinichi Togami

  3. Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

    Yuko Sasajima, Rie Oda-Otomo & Hitoshi Tsuda

  4. Department of Pathology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan

    Yuko Sasajima

Authors
  1. Shinichi Togami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuko Sasajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Kasamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rie Oda-Otomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitsuya Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shun-ichi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomoyasu Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hitoshi Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinichi Togami.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Togami, S., Sasajima, Y., Kasamatsu, T. et al. Immunophenotype and Human Papillomavirus Status of Serous Adenocarcinoma of the Uterine Cervix. Pathol. Oncol. Res. 21, 487–494 (2015). https://doi.org/10.1007/s12253-014-9854-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-014-9854-y

Keywords

Search

Navigation